Elevated Platelet Count
Essential thrombocythemia with platelet count typically greater than 600,000/µL
Reactive thrombocytosis from:
iron deficiency anemia
acute blood loss
rebound from marrow suppression or immune thrombocytopenia
Platelet counts greater than 1,000,000/µL are worrisome for acute thrombotic events.
Elevated platelet count with poorly functioning platelets does not present an increased risk for thrombosis.
Commonly Encountered Situations
Reactive thrombocytosis from a variety of causes is far more common than essential thrombocythemia (a chronic myeloproliferative disorder).
Suggested Additional Lab Testing
Test that reveals any of the causes of reactive thrombocytosis previously noted are valuable.
Tests to confirm the presence of essential thrombocythemia include:
bone marrow biopsy to show an increase in the number of megakaryocytes
normal RBC mass to exclude polycythemia vera
platelet aggregation study showing a selective impaired aggregation response only to epinephrine suggests essential thrombocythemia
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
- Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma
- Impact of Prostate Cancer Diagnosis, Treatment Choice on Quality of Life
- Axillary Lymph Node Dissection Predictive for Lymphedema in Breast Cancer
- Duloxetine May Improve AI-Associated Joint Pain in Early Stage Breast Cancer
- Extended Adjuvant Therapy for Breast Cancer Improves 5-Year Disease-free Survival
- HPV and Cancer (Fact Sheet)
- Pain Control More Easily Achieved With Nurse-Led Education in Bone Metastases
- Acupuncture an Effective Alternative Treatment for Cancer-Related Fatigue
- Using Nutrition-Based Strategies to Manage Adverse Effects of Cancer
- Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer
- Refined Equation May Obviate Oncotype DX in Breast Cancer Treatment Decisions
- Risk Factors for Brain Metastases in HER2+ Breast Cancer Identified in Analysis
- Intermediate Oncotype DX Scores Prognostic of OS in Early-stage Breast Cancer
- Colorectal Cancer and Dietary Fiber: Source Is More Important Than Amount
- Reduced Delayed Intensification Impacts Risk of Pediatric ALL Relapse
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|